AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

RHYTHM PHARMACEUTICALS, INC. Director's Dealing 2025

Feb 14, 2025

30849_dirs_2025-02-14_4dde3731-72b2-42ac-8efb-aba22c1e440c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2025-02-12

Reporting Person: Lee Jennifer Kayden (EVP, Head of North America)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-12	Common Stock	S	600	$56.39	Disposed	4813	Direct
2025-02-12	Common Stock	S	10	$56.41	Disposed	4803	Direct
2025-02-12	Common Stock	S	1205	$56.39	Disposed	3598	Direct
2025-02-13	Common Stock	S	1205	$58	Disposed	2393	Direct

Footnotes

F1: The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.

F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024.